CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <\/p>\n
Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic diagnostic testing and analysis to routine clinical care, today announced the companys participation in multiple sessions and presentations at the American Association for Cancer Research (AACR) Annual Meeting 2013 taking place April 6-10, 2013 in Washington, D.C. <\/p>\n
The clinical benefit of comprehensive genomic profiling in cancer care is becoming increasingly clear as Foundation Medicine continues to present new clinical and research findings, said Vincent Miller, M.D., senior vice president, clinical development, Foundation Medicine. The collaborative studies and sessions at AACR should help advance the application of genomics and next-generation sequencing in clinical practice, and it is gratifying to see such encouraging progress. <\/p>\n
The schedule for Foundation Medicines presentations and posters is as follows: <\/p>\n
Date & Time: Saturday, April 6, 2013 from 10:15 to 10:40 a.m. ET Title: Clinical application of genome profiling in lung cancer Session: Future directions in personalized medicine for lung cancer Type: Educational Session Location: Room 143, Washington Convention Center Presenter: Vincent Miller, M.D., senior vice president, clinical development, Foundation Medicine <\/p>\n
Date & Time: Sunday, April 7, 2013 from 1:00 to 5:00 p.m. ET Title: Differences in genomic alterations revealed by sequencing of 182 genes in recurrent ovarian cancer specimens compared to TCGA analysis: rearrangements in PTCH1 and FLT3; high frequency of RAS pathway alteration Abstract Number: 58 Session: Molecular Diagnostics Type: Poster Session Location: Hall A-C, Poster Section 3 Presenter: Deborah A. Zajchowski, Ph.D., scientific director, The Clearity Foundation (research in collaboration with Foundation Medicine) <\/p>\n
Date & Time: Monday, April 8, 2013 from 1:00 to 5:00 p.m. ET Title: Identification of a novel genetic abnormality, the amplification of rictor (rapamycin-insensitive companion of mTOR), in a patient with non-small cell lung cancer Abstract Number: 2033 Session: Combination Therapies and Novel Therapeutic Approaches Type: Poster Session Location: Hall A-C, Poster Section 36 Presenter: Haiying Cheng, M.D., assistant professor, department of medicine, Albert Einstein College of Medicine of Yeshiva University (research in collaboration with Columbia University and Foundation Medicine) <\/p>\n
Date & Time: Monday, April 8, 2013 from 1:00 to 5:00 p.m. ET Title: Next generation sequencing demonstrates multiple gene amplifications and mutations in 3 patients with estrogen receptor-positive breast cancer with responses to treatment with combination aromatase and PI3K\/AKT\/mTOR pathway inhibition Abstract Number: 1209 Session: Molecular Classification of Tumors Type: Poster session Location: Hall A-C, Poster Section 3 Presenter: Ralph Zinner, M.D., associate professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center (research in collaboration with Foundation Medicine) <\/p>\n
Date & Time: Monday, April 8, 2013 from 3:00 to 5:00 p.m. ET Title: Bringing next generation sequencing (NGS) to the clinic: Analytical validation of a comprehensive NGS-based cancer gene test Abstract Number: 2279 Session: Identification of New Targets and Pathways in Cancer: Translating Basic Discoveries into the Clinic Type: Minisymposium Location: Room 207, Washington Convention Center Presenter: Roman Yelensky, director, clinical genomic analysis, Foundation Medicine <\/p>\n
Date & Time: Tuesday, April 9, 2013 from 8:15 to 10:15 a.m. ET Session: Regulatory Considerations for Integrative Biomarker Development Using Whole Genome Technologies Type: Regulatory Science and Policy Session Location: Room 144, Washington Convention Center Presenter: Vincent Miller, M.D., senior vice president, clinical development, Foundation Medicine <\/p>\n
<\/p>\n
Continue reading here: <\/p>\n
Foundation Medicine to Present Cancer Genomic Research and Clinical Findings at the AACR Annual Meeting 2013<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic diagnostic testing and analysis to routine clinical care, today announced the companys participation in multiple sessions and presentations at the American Association for Cancer Research (AACR) Annual Meeting 2013 taking place April 6-10, 2013 in Washington, D.C. The clinical benefit of comprehensive genomic profiling in cancer care is becoming increasingly clear as Foundation Medicine continues to present new clinical and research findings, said Vincent Miller, M.D., senior vice president, clinical development, Foundation Medicine. The collaborative studies and sessions at AACR should help advance the application of genomics and next-generation sequencing in clinical practice, and it is gratifying to see such encouraging progress Continue reading